Neumora Therapeutics Inc (NMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.49-13.96%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NMRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
NMRA — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-10-30
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 26, 2026, Neumora Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period…
Why it matters: These steps would move NMRA-215 from animal tests into human testing for obesity and heart-risk disease.
Supportive ifNeumora files the NMRA-215 IND in Q4 2026 and starts Phase 1 by year-end.
Worry ifThe IND filing or Phase 1 start slips beyond year-end, or the company reports new safety findings.
Why it matters: The data will help guide dose choice for the planned Phase 2 study in Alzheimer’s agitation.
Watch forQ4 2026 results show the higher-dose group was safe and support moving to a Phase 2 study by year-end.
Also watch forThe data show safety concerns, or the company delays or drops the planned Phase 2 study.
Why it matters: Neumora reported $116.8 million in cash and said it could fund its plan into Q3 2027. A shorter runway could limit study plans.
Worry ifThe Nov. 5 update keeps the cash runway into Q3 2027 or gives a later end date.
Less concerning ifThe Nov. 5 update moves the cash runway to before Q3 2027 or cites a need to cut or delay planned studies.
Why it matters: Nasdaq says NMRA is below its $1 minimum bid price rule. The next notice or filing can show the listing risk.
Worry ifA company filing says NMRA remains below $1 and has not regained compliance by the stated deadline.
Less concerning ifA company filing says NMRA regained compliance with the $1 minimum bid rule.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$392 on $10,000 · ±3.9% | How much price usually moves either way. |
| Bad day | $843 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,013 loss on $10,000 · 90.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The study data will show whether NMRA-898 can move forward in schizophrenia.
Watch forThe company reports Phase 1 data in H2 2026 with no major safety issues and plans the next study step.
Also watch forThe data show safety issues, or the company delays or stops the program.